Please assess the completion status of the following clinical trial:

Trial Title: Coenzyme Q10 and Clomiphene Citrate (CC) for Ovulation Induction in Polycystic Ovary Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of PCOS based on the revised 2003 consensus on diagnostic criteria and long-term health risks related to PCOS (2003).~* All women were previously treated with 100 mg of CC daily for 5 days per cycle, for two to three cycles with persistent anovulation or ovulate with very thin endometrium \<5 mm at the time of hCG administration~Exclusion Criteria:~* patients with hyperprolactinaemia,~* hypercorticism and~* thyroid dysfunction.~* patients receiving medications as cholesterol lowering drugs, as statins, beta-blockers, and tricyclic antidepressants

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Coenzyme Q10/CC group (Type: EXPERIMENTAL): Intervention:~Coenzyme Q10 (CoQ10) and clomiphene citrate group (55 patients, 82 cycles) Patients in CoQ10/CC group took CC (Global Napi, Cairo, Egypt) 100 mg/day from cycle days 2-6, and CoQ10 Mepaco, Enshas Elraml, Sharkhia, Egypt), in a dose of 60 mg 3 times day capsules orally starting on cycle day 2 and continued till the day of human chorionic gonadotropin (hCG) administration
- CC alone group (Type: ACTIVE_COMPARATOR): Intervention:~CC (Global Napi, Cairo, Egypt) 100 mg/day from cycle days 2-6

Based on this trial design, predict the completion outcome and termination type (if applicable).